Calculation of inhibitor Ki and inhibitor type from the concentration of inhibitor for 50% inhibition for Michaelis-Menten enzymes

https://doi.org/10.1016/0885-4505(87)90046-6Get rights and content

Abstract

The use of I50 (concentration of inhibitor required for 50% inhibition) for enzyme or drug studies has the disadvantage of not allowing easy comparison among data from different laboratories or under different substrate conditions. Modifications of the Michaelis-Menten equation for treatment of inhibitors can allow both the determination of the type of inhibition (competitive, noncompetitive, and uncompetitive) and the Ki for the inhibitor. For competitive and uncompetitive inhibitors when the assay conditions are [S] = Km, then Ki = I502. For different conditions of [S] there is a divergence between competitive and uncompetitive inhibitors that may be used to identify the type of inhibitor. The equation for Ki also differs. For noncompetitive inhibitors the Ki = I50 and this relationship is valid with changing [S]. The equations developed require a single substrate, reversible-type inhibitors, and kinetics of the Michaelis-Menten type. Examples of the use of the equations are illustrated with experimental data from scientific publications.

References (6)

  • R.B. Brandt et al.

    Biochem. Med.

    (1983)
  • J.H. Wilkinson et al.

    Clin. Chim. Acta

    (1968)
  • J.L. Webb
There are more references available in the full text version of this article.

Cited by (66)

  • Kinetic mechanisms of covalent inhibition

    2021, Annual Reports in Medicinal Chemistry
    Citation Excerpt :

    The same principle applies to covalent inhibition as although the protein is irreversibly inhibited once the covalent E-I complex has formed, the initial reversible binding event to form the EI complex will still be affected by the substrate concentration and the inhibitor's mechanism of action. If the mechanism of action for the reversible step of covalent inhibition is known, the apparent KI may be corrected for substrate concentration.32,62,63 Due to limitations with solubility of the substrate or sensitivity of the detection system (which may require the use of comparatively low or high concentrations of the substrate relative to its KM) it is not always possible to run an assay at a substrate concentration equivalent to KM.32,33

  • Kinetic modelling of in vitro data of PI3K, mTOR1, PTEN enzymes and on-target inhibitors Rapamycin, BEZ235, and LY294002

    2017, European Journal of Pharmaceutical Sciences
    Citation Excerpt :

    These relations can be also used in the analysis of variation in the IC50 values for LY294002 and BEZ235 inhibitors in cancer lines characterizing by different ATP levels (Moreno-Sánchez et al., 2014; Zhou et al., 2012). Note that according to the model of mTOR1 kinase (Eqs. (1) and (2)) and general properties of MM approximation (Brandt et al., 1987; Yung-Chi and Prusoff, 1973) the IC50 value for allosteric inhibitor Rapamycin does not depend on ATP concentration and its IC50 is equal to the dissociation constant of Rapamycin Kd,Rap in relation to Eq. (6). This result is in agreement with experimental IC50 values (2 nM and 7 nM for S6K1 and 4EBP1 respectively) which are close to theoretical dissociation constants Kd,Rap = 1.5 ± 0.5 nM and 7 ± 1.1 nM respectively (Table 1).

View all citing articles on Scopus
View full text